Thyroid disease research

(a) In general The Secretary, in consultation with the National Academies of Sciences, Engineering, and Medicine, shall— (1) conduct or support research and related activities regarding thyroid disease, including research— (A) to investigate the root causes of thyroid disease; (B) to improve diagnostic techniques and develop improved treatments; (C) to improve thyroid cancer-related care, including the prevention, diagnosis, and treatment of thyroid nodules and thyroid cancer; (D) to enhance the quality of thyroid cancer survivorship, including understanding how a thyroid cancer diagnosis impacts women of reproductive years and beyond; (E) to understand the symptoms of patients treated for thyroid disease and to design studies to improve symptom management; (F) to assess— (i) thyroid disease prevalence, detection, treatment, and outcome disparties by race, ethnicity, geography, primary language, sex, sexual orientation, gender identity, disability status, and insurance status, and related topics as determined by the Secretary; and (ii) with respect to thyroid cancer patients, such disparities relating to primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment; and (G) to study the effects of thyroid disease, including subclinical hypothyroidism, in patients who continue to experience symptoms despite their test results becoming normal; and (2) propose recommendations on how to address research gaps relating to disparities referred to in paragraph (1)(F). (b) Interim report The Secretary shall— (1) not later than 24 months after the date of enactment of this Act, transmit an interim report on the status and results of the research and related activities under this section to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate; and (2) make such report publicly available. (c) Authorization of appropriations To carry out this section, there is authorized to be appropriated $30,000,000 for each of fiscal years 2026 through 2030.